Maia Biotechnology, Inc.

MAIA

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001878313


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $9.7M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, thin data, degenerate inputs not computable: short runway, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 23, 2026 229 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026
Last close	$1.05 2026-11-06; market equity $63.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 23, 2026

MAIA Biotechnology, Inc. (MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Ateganosine (THIO, 6-thio-dG or 6-thio-2 ?-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In July 2022, the first patient was administered with ateganosine in our Phase 2 human trial (THIO-101) in Australia. In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101, Phase 2 clinical trial evaluating ateganosine in patients with Non-Small Cell Lung Cancer (NSCLC).

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 11.2						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(35.8%)	(6.6%)	11.2	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 83.1					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(50.68)	(0.37)	89.1	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	1.66x	2.94x	77.1	828	2025-12-31
Growth and financing, sleeve percentile 73.8					
Revenue growth, three-year compound	not computable	10.0%			
four annual observations are required; found 3					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(6.9%)	2.2%	65.0	696	2025-12-31
Net share issuance, one year	105.1%	2.5%	82.5	630	2026-03-23

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 105.1%
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(4.8%)	(2.1%)	48
Distance from 52-week high	(64.1%)	(30.5%)	17
EBIT to enterprise value	(37.6%)	(1.5%)	17
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.32	0.29	54
Sales to price	0.00	0.30	0
Composite equity issuance, five years	not computable	21.4%	
Relative strength against the sector, log excess return	(0.22)	(0.19)	48

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$0
Operating cash flow, four quarters	-$22.6M
Months of runway	not finite
Days since last periodic filing	89 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	$429,983

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$22.4M	2025-12-31	2026-03-23	10-K	26-012088
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.8M	2025-12-31	2026-03-23	10-K	26-012088
3	assets	us-gaap:Assets	$9.7M	2025-12-31	2026-03-23	10-K	26-012088
4	assets	us-gaap:Assets	$10.2M	2024-12-31	2026-03-23	10-K	26-012088
5	current assets	us-gaap:AssetsCurrent	$9.7M	2025-12-31	2026-03-23	10-K	26-012088
6	current liabilities	us-gaap:LiabilitiesCurrent	$5.8M	2025-12-31	2026-03-23	10-K	26-012088
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$109.6M	2025-12-31	2026-03-23	10-K	26-012088
8	operating income	us-gaap:OperatingIncomeLoss	-$24.3M	2025-12-31	2026-03-23	10-K	26-012088
9	book equity	us-gaap:StockholdersEquity	$2.4M	2025-12-31	2026-03-23	10-K	26-012088
10	liabilities	us-gaap:Liabilities	$7.3M	2025-12-31	2026-03-23	10-K	26-012088
11	operating income	us-gaap:OperatingIncomeLoss	-$17.0M	2024-12-31	2026-03-23	10-K	26-012088
12	interest expense	us-gaap:InterestExpense	$57	2024-12-31	2025-03-21	10-K	25-043190
13	revenue	us-gaap:Revenues	$0	2024-12-31	2025-03-21	10-K	25-043190
14	revenue	us-gaap:Revenues	$0	2023-12-31	2024-03-21	10-K	24-034764
15	revenue	us-gaap:Revenues	$0	2022-12-31	2023-03-24	10-K	23-009766
16	assets	us-gaap:Assets	$7.6M	2023-12-31	2025-03-21	10-K	25-043190
17	assets	us-gaap:Assets	$12.0M	2022-12-31	2024-03-21	10-K	24-034764
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	60,671,491	2026-03-23	2026-03-23	10-K	26-012088
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	29,587,314	2025-03-21	2025-03-21	10-K	25-043190

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.